We are excited to bring these products to our customers to support the health and wellness of children, adults and sports enthusiasts around the world.
Wilmington, DE (PRWEB) November 12, 2013
DuPont has launched a family of HOWARU® Protect probiotics targeted for children, adults and sports enthusiasts. All three formulations are clinically documented to help maintain natural immune defenses. The HOWARU® Protect range is available to dietary supplement and food and beverage manufacturers focused on improving consumer health:
- HOWARU® Protect Kids helps keep children healthy during the cold and flu season. Based on a study published in Pediatrics*, results showed that HOWARU® Protect Kids supported respiratory health with symptom duration shortened from 6.5 to 3.5 days; a strong reduction in antibiotic use and a reduced number of sick days.
- HOWARU® Protect Adult helps maintain a healthy respiratory function. Based on a study recently published in Clinical Nutrition*, data demonstrated a 27 percent reduction of risk of upper respiratory tract illness coupled with the delayed onset of respiratory tract illness versus the placebo.
- HOWARU® Protect Sport helps physically active adults stay healthy for optimal sports performance. Based on a study published in Clinical Nutrition*, the formulation promoted a greater level of physical activity; significantly extended exercise duration; significantly improved training intensity and delayed the onset of respiratory infections.
"We are excited to bring these products to our customers to support the health and wellness of children, adults and sports enthusiasts around the world," said Fabienne Saadane-Oaks, vice president Health and Protection, DuPont Nutrition & Health. "Probiotics is a fast-growing segment of our business as people increasingly experience the benefits they can provide. Our HOWARU® Protect formulations have been clinically tested and shown to deliver the immune support people need."
According to industry estimates, the global retail market for probiotics is estimated at $32 billion in 2013 and is expected to grow to $45 billion in 2018. More than 90 percent of the total is attributed to food, beverage and dietary supplements.
The research supporting HOWARU® premium probiotics has been communicated in many peer-reviewed journals and scientific publications, and presented at a number of scientific conferences. DuPont Nutrition & Health scientists partner with a global network of academics, clinicians and other experts in the field, allowing the business to continuously build on the health benefits of its ingredients.
The World Health Organization defines probiotics as "live micro-organisms which, when administered in adequate amounts, confer a health beneﬁt on the host." Probiotics offer unique support for digestive and immune health and other well-being benefits for the dietary supplement, dairy and beverage markets.
DuPont Nutrition & Health addresses the world’s challenges in food by offering a wide range of sustainable, bio-based ingredients and advanced molecular diagnostic solutions to provide safer, healthier and more nutritious food. Through close collaboration with customers, DuPont combines knowledge and experience with a passion for innovation to deliver unparalleled customer value to the marketplace.
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, non-governmental organizations, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.
Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products; and severe weather events that cause business interruptions, including plant and power outages, or disruptions in supplier and customer operations. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.
# # #
The DuPont Oval Logo, DuPont™, The miracles of science™ and HOWARU® are registered trademarks or trademarks of DuPont or its affiliates.
*HOWARU® Protect Kids: Benefits delivered at 10 billion CFU of Bifidobacterium lactis Bi-07™ and Lactobacillus acidophilus NCFM®; HOWARU® Protect Adult: Benefits delivered at 2 billion CFU of Bifidobacterium lactis Bl-04™; HOWARU® Protect Sport: Benefits delivered at 10 billion CFU of Bifidobacterium lactis Bi-07™ and Lactobacillus acidophilus NCFM®.